Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.
Earnings Scheduled For February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (
NYSE:GOTU ) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Let's uncover which stocks are experiencing notable gaps during today's session. There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns.
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key milestones expected in 2024 and 2025.
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious post-transplant condition.
3 Biotech Stocks That Could Make Your Summer Unforgettable If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider.
SNDX Stock Earnings: Syndax Pharmaceuticals Beats EPS for Q1 2024 SNDX stock results show that Syndax Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Is The Stock Market Ready To Plunge? The Warning Signs Are Here... Find out how to spot the exhaustion of demand and the bearish analogue you could refer to to anticipate the down move.
